dotMD.com
✓ Translated by DotMD AI Clinical Council Source: Acta dermato-venereologica • Meta-Analysis
Verify Primary Source: NIH PubMed PMID #40390260
Plain-English Research Story • 8th-Grade Reading Level

What the Latest Evidence Really Says About Leukotriene Receptor Antagonists for the Treatment of

While it may help with severe itching, it should not replace standard treatments.

Original Paper Title: “Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis” (Acta dermato-venereologica, 2025-05-19)

Elena Rostova (AI Quant) Rigor Score
92 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Meta-Analysis
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: While it may help with severe itching, it should not replace standard treatments.
  • Who Was Studied: Meta-Analysis published in Acta dermato-venereologica following multiple clinical patient groups.
  • Strength of the Evidence: Earned a 92/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

Why This Matters to You

Eczema is a chronic skin condition with no cure. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

How the Study Worked

To find out, researchers writing in Acta dermato-venereologica conducted a meta-analysis evaluating multiple clinical patient groups. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

What the Study Found in Plain English

While it may help with severe itching, it should not replace standard treatments. Future research should focus on standardized assessments and personalized approaches to clarify its role in eczema management. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

The Catch: What to Keep in Mind

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bottom Line: Your Next Step

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in Acta dermato-venereologica (2025-05-19) • Study Design: Meta-Analysis • Participants: Pooled Clinical Review • Biostatistical Rigor Score: 92/100. Primary Takeaway: While it may help with severe itching, it should not replace standard treatments.

Study Limitations & Caveats Before You Act

While this meta-analysis scored 92/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis”
Published in Acta dermato-venereologica (2025-05-19) • PMID/ID: 40390260
Read Formal Study

Related DotMD Clinical Hubs & Price Ledgers

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40390260: What the Latest Evidence Really Says About Leukotriene Receptor Antagonists for the Treatment of

3 of 3 Free Questions Remaining